VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Individuals with MASLD with a lean vs nonlean body type have increased mortality and cardiovascular disease, among other outcomes.

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, researchers in Italy have found.

The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...